Mylan Pharmaceuticals is expanding its recall of high blood pressure and heart failure treatments to include all its products that contain the active ingredient valsartan because they may contain trace amounts of a potentially cancer-causing impurity. The 104 additional lots involved in the recall include varying doses of 26 lots of amlodipine and valsartan tablets, 51 lots of valsartan tablets, and 27 lots of valsartan and hydrochlorothiazide tablets. The tablets were distributed nationwide from March 2017 to November 2018. A list of affected drugs can be found on Mylan’s recall notice. The impurity found in the drugs is N-nitrosodiethylamine (NDEA), ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.